Breakthrough Pill Doubles Survival for Pancreatic Cancer | San Diego News

Pancreatic cancer just got a major breakthrough: the FDA approved daraxonrasib, a daily pill targeting a key mutated protein driving most tumors. In trials, patients lived nearly twice as long—13.2 months vs. 6.7—with fewer severe side effects. Though pricey at $39,800 per month, it’s a game-changer for a disease with few options. Fast-tracked by the FDA, this drug could pave the way for new treatments in lung cancer and beyond—marking not just a win for pancreatic cancer, but potentially a new era in oncology. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/13239e9e1e354659